CQDM. We grow.CQDM is proud to announce the addition of a new member to its team! Welcome to Aren Bezdjian, PhD who joins as Manager, Special Projects. Before joining CQDM, Aren worked as a senior clinical research manager at the Montreal Neurological Institute and for Oticon Medical. Together with his teams, he developed and led…
ABOUT CQDM Since its inception, CQDM has raised more than $275 million to fund the development of 150 + drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and…
Montreal, August 10th, 2023 – CQDM is proud to present a new series of events: Connect-Pharma. CQDM launches Connect-Pharma, with a first event for fall 2023: Pitch Day. CQDM is pleased to launch a call for ideas for our new Connect-Pharma: Pitch Day event. We are searching for world-class research to develop novel and efficient approaches for…
ABOUT CQDM Since its inception, CQDM has raised more than $275 million to fund the development of 150 + drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and…
ABOUT CQDM Since its inception, CQDM has raised more than $275 million to fund the development of 150 + drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and…
Challenge: Human cells eliminate non-functional proteins using a sophisticated degradation pathway named the ubiquitin proteasome system (UPS), in which UPS enzymes attach a small protein called ubiquitin to damaged target proteins to tag them for degradation. However, abnormalities in protein degradation are frequently observed in many diseases, including cancer where aberrant control of protein degradation…
Challenge: The sensory neuron damage referred as “Chemotherapy-Induced Peripheral Neuropathy” (CIPN) affects 30-40% of cancer patients in Canada. Sensory neurons transmit information from the brain to every other part of the body allowing movement and awareness of our environment. The deterioration of these cells from chemotherapy causes severe pain often leading to the interruption of…
Challenge: Nuclear receptors (NRs) are a family of proteins that regulate gene expression in many vital processes such as metabolism, growth and behaviour. They are also implicated in a large array of diseases such as diabetes, Parkinson’s, Alzheimer’s and cancer. Consequently, nuclear receptors represent one of the most important class of targets for existing drugs.…
Challenge: A major problem with protein-based therapeutics is their immunogenicity, i.e. their tendency to trigger an unwanted immune response against themselves. This leads to the activation of immune cells and secretion of anti-drug antibodies (ADA) that may contribute to an inactivation of the biologics and cause adverse clinical events. Therefore, there is a need in…
Challenge: Silencing RNAs (siRNAs) are small nucleic acids that can inhibit virtually any gene. Because most diseases could benefit from shutting-down the action of a specific protein encoded by its gene, it is suggested that siRNAs could be used to treat virtually any diseases. However, naked siRNA is unstable in the bloodstream and cannot efficiently…